Important Notice: Limited Web Access Dec 16 to 18, 2016

AIChE will undertake a routine upgrade of our digital infrastructure over the weekend of December 16-18, 2016. During this period access to certain areas of the website will be limited. Additional information will be forthcoming shortly.

Session I: Robust Process and Product Design: Accommodating Uncertainty

Session I: Robust Process and Product Design: Accommodating Uncertainty
Wednesday, June 6, 2012, 9:45am-11:45pm EDT

Session Co-Chairs

  • Jean Tom, Bristol-Myers Squibb
  • Dan Pintar, UOP LLC


Investigation of the Impact of Mode of Operation (Batch vs Flow) on Design Space MapShankar Vaidyaraman
Management for New Process Technology Implementation – Some Key ComponentsMichael Schaller
Biopharmaceutical Purification Process Development: Identifying Risks and Dealing with UncertaintySteven Weisser

Investigation of the Impact of Mode of Operation (Batch vs Flow) on Design Space Map

Shankar Vaidyaraman, Eli Lilly and Company

This talk will discuss how the mode of operation (batch vs flow) impacts the design space map for impurities thus impacting the robustness of the process. A specific case study involving a reaction model will be used for this investigation that builds upon previous work on failure mode analysis in continuous processes (Wong etal 2011). There are three impurities of interest formed in this reaction. A reaction kinetic model developed from batch experiments is used to design for both batch and flow processes. The key questions that this investigation addresses are:

  • How much does the mode of operation impact the size of the design space?
  • Is the link between the uncertainties due to routine variability and model uncertainty and the output impurity levels same or different depending on the mode of operations?
  • Can certain generalizations be drawn based on the results of this case study?

Management for New Process Technology Implementation – Some Key Components

Michael Schaller, The Dow Chemical Co

As The Dow Chemical Company continues to increase our emphasis on innovation to meet customer needs, more and more of our capital projects incorporate new process technology, new product technology, or both. Although all capital projects include some degree of risk, we’ve determined that projects involving new process technology face more significant risks. For example, building a new polyethylene manufacturing facility using previously-demonstrated technology may face risks related to material and labor costs, scheduling and/or Environmental, Health and Safety (EH&S) issues. But building a facility to make a new pesticide, the process for which has not been fully demonstrated at the lab scale, and doing it in time to meet the seasonally-driven launch date, poses the same potential cost, schedule and EH&S risks, but also includes operability risks, risks associated with the overlap of process development and process design, a compressed project schedule, limited understanding of the relationship between process variables and product performance, etc.

Because our capital project work processes, and, to some extent, our culture, were developed around building commodity chemical manufacturing facilities, we treat projects involving new process technology (NPT) differently than we do those implementing demonstrated technology. One area that we focus on is risk assessment and risk management. Some of the key aspects of dealing effectively with new process technology implementation that we will share are the following:

  • Incorporate inherently low-risk approaches
  • Fill and support the Risk Manager role
  • Develop and implement a formal Risk Management Plan
  • Develop and maintain a detailed plan for Technology Development
  • Practice quantitative risk assessment
  • Prepare for problems

Biopharmaceutical Purification Process Development: Identifying Risks and Dealing with Uncertainty

Steven Weisser, GlaxoSmithKline

Process and product knowledge is gained throughout the lifecycle of a biopharmaceutical product. Process development teams need to use purification strategies that allow them to respond to new information and accommodate uncertainty. Development of biopharmaceutical purification processes will be discussed with an emphasis on how project teams deal with uncertainty.

Strategies focusing on identification of risks and knowledge gaps, and designing and implementing mitigation plans to deal with them will be discussed. Application of these approaches to problems such as dealing with feed stream variability, risks to key raw materials, and issues observed after scale-up will be presented.

Dr. Michael Schaller

Michael Schaller is the Process Technology Risk Assessment Global Leader for The Dow Chemical Company. Schaller joined Dow in 1987 after receiving his B.S. in Chemical Engineering from the University of Wisconsin.  His Dow career has been spent nearly equally in three different functions: manufacturing, process engineering and R&D.

Schaller’s manufacturing roles include production engineer, improvement engineer, process control engineer, capital project leader and production coordinator.  As a process engineer, Schaller supported capital and asset improvement projects in a...Read more

Dr. Shankar Vaidyaraman

Dr. Vaidyaraman is Associate Senior Consultant engineer for Chemical Product R&D at Eli Lilly and Company in Indiana. He joined Eli Lilly and worked for seven years in Marketing employing analytics to support business decisions. His current role for the past four years has been to support process definition and optimization activities within Chemical Product R&D at Eli Lilly and Company.

He received his Ph.D. in Chemical Engineering from Penn State University in 2001.Read more

Mr. Steven M. Weisser

Steven Weisser is a Senior Scientist in the Biopharmaceutical Development group at GlaxoSmithKline, where he works on downstream processing of therapeutic proteins.  In this role, he is responsible for developing and characterizing purification processes and transferring them from the lab scale to manufacturing facilities for GMP production of a biopharmaceutical product.

Prior to joining GSK, Steven worked in the process development group at ImClone Systems Incorporated, where he developed and transferred purification processes for early-phase and commercially approved monoclonal...Read more